<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648592</url>
  </required_header>
  <id_info>
    <org_study_id>PI 19-1342</org_study_id>
    <nct_id>NCT04648592</nct_id>
  </id_info>
  <brief_title>Salt Intake, Microbiota, Immune Response and Endothelial Function in Hypertension</brief_title>
  <official_title>Impact of Salt Intake on Gut Microbiota, Th17 Immune Response and Endothelial Function in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clínico Universitario de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is a significant cardiovascular risk factor which affects 45% of the adult&#xD;
      population. Salt intake is essential in the development and progression of hypertension. A&#xD;
      reduction in salt intake is associated with a reduction in blood pressure and a 25% lower&#xD;
      risk of suffering a cardiovascular event. The mechanisms involved in the association between&#xD;
      salt intake and blood pressure are a topic of discussion. Increased salt intake can modify&#xD;
      cardiovascular function, inducing endothelial dysfunction, modyfing the activity of the&#xD;
      immune system and increasing inflammation or oxidative stress.&#xD;
&#xD;
      In recent years, dietary salt intake has been linked to intestinal depletion of certain&#xD;
      genera of bacteria such as Lactobacillus. Tryptophan metabolites formed by these bacteria&#xD;
      have been shown to modulate the activity of pro-inflammatory cells such as Th17/CD4+,&#xD;
      interleukin 17a producing cells. Studies in animal models have demonstrated that interleukin&#xD;
      17a is able to raise blood pressure by hindering endothelium-dependent vasodilation&#xD;
      mechanisms. It is also able to cause sodium and water retention, increase albuminuria, induce&#xD;
      renal microvascular injury and vasoconstriction and promote vascular stiffening, cardiac&#xD;
      hypertrophy and fibrosis.&#xD;
&#xD;
      The main objective of this trial is to describe the relationship between salt intake, gut&#xD;
      commensal microbiota, Th17 activity, endothelial dysfunction and blood pressure evolution in&#xD;
      a sample of patients with essential hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, double blind clinical trial.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Trial participants, care providers and study investigators will be blinded to assigned interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in lymphocyte subset counts</measure>
    <time_frame>30 days</time_frame>
    <description>Lymphocyte subset counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change in gut microbiota composition daily total salt</measure>
    <time_frame>30 days</time_frame>
    <description>Taxonomic metagenomic analysis, analyzing the composition at the level of family, genus and species. Percentage of variation of each species in each control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in body composition assessed by electrical bioimpedance</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of change in total body water, total intracellular water, total extracellular water, fat mass, percentage of fat, lean mass, and muscle-skeletal mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in peak and average 24h ambulatory blood pressure measurement</measure>
    <time_frame>30 days</time_frame>
    <description>24h ambulatory blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in endothelial function</measure>
    <time_frame>30 days</time_frame>
    <description>Pulse wave velocity analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low salt diet plus sodium chloride supplements</intervention_name>
    <description>Patients will receive a low salt diet plus salt supplements.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low salt diet plus placebo</intervention_name>
    <description>Patients will receive a low salt diet plus placebo.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Diagnosis of primary hypertension on treatment for at least 12 months with an ACEI or&#xD;
             ARB-II in monotherapy.&#xD;
&#xD;
          -  Able to understand the study objectives and to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hypertension, defined as a sitting systolic blood pressure ≥200 mmHg, a sitting&#xD;
             diastolic blood pressure ≥115 mmHg or a maximum-minimum difference of ≥20 mmHg in&#xD;
             systolic blood pressure or ≥10 mmHg in diastolic blood pressure between the right and&#xD;
             left arms after three measurements on each arm.&#xD;
&#xD;
          -  Suggestive symptoms of secondary hypertension, such as abrupt onset hypertension, age&#xD;
             &lt;30 years, advanced end organ damage, new-onset diastolic hypertension in the elderly,&#xD;
&#xD;
          -  Treated with antihypertensive drugs other than ACEIs or ARBs.&#xD;
&#xD;
          -  Use of drugs that affect diuresis or natriuresis.&#xD;
&#xD;
          -  Poorly controlled type 1 or 2 diabetes, defined as a fasting blood glucose ≥200 mg/dl&#xD;
             or HbA1c ≥9%.&#xD;
&#xD;
          -  History of cardiovascular disease, defined as acute myocardial infarction, ischemic&#xD;
             transient attack or stroke, congestive heart failure, peripheral vascular disease or&#xD;
             cardiac arrhythmias.&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Liver or kidney disease.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Legal incapacity or impossibility to understand the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Coca, MD, MSc, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Valladolid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Coca, MD, MSc, phD</last_name>
    <phone>983420000</phone>
    <email>a.coca.rojo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Coca, MD, PhD</last_name>
      <phone>630841439</phone>
      <email>a.coca.rojo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Armando Coca, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valladolid</investigator_affiliation>
    <investigator_full_name>Armando Coca Rojo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Salt intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study data will be shared upon reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

